ANTILEUKEMIC ACTIVITY OF THE TYROSINE KINASE INHIBITOR BVT II plus /- CYTARABINE OR DAUNORUBICIN IN ACUTE MYELOID LEUKEMIA

被引：0
|
作者：
Eriksson, A. [1 ]
Hassan, S. Bashir [1 ]
Hoglund, M. [1 ]
Larsson, R. [1 ]
Lindhagen, E. [1 ]
Aleskog, A. [1 ]
Fohlenhag, K. [2 ]
Jensen, A. Jenmalm [2 ]
Lehmann, F. [2 ]
Lothgren, A. [2 ]
Parrow, V. [2 ]
机构：
[1] Uppsala Univ, Uppsala, Sweden
[2] Biovitrum AB, Discovery Res, Stockholm, Sweden
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0290
引用
收藏
页码：118 / 118
页数：1
相关论文
共 50 条
  • [21] DAT (DAUNORUBICIN, CYTARABINE, 6-THIOGUANINE) IN ACUTE MYELOID-LEUKEMIA
    REES, JKH
    HAYHOE, FGJ
    LANCET, 1978, 1 (8078): : 1360 - 1361
  • [22] The multitargeted tyrosine kinase inhibitor sorafenib enhances the activity of cytarabine in acute myelogenous leukemia by increasing intracellular phosphorylated metabolites
    Niu, Hongmei
    Hu, Shuiying
    Inaba, Hiroto
    Rubnitz, Jeffrey
    Orwick, Shelley
    Panetta, John
    Schuetz, John
    Baker, Sharyn
    CANCER RESEARCH, 2009, 69
  • [23] Venetoclax plus daunorubicin and cytarabine in newly diagnosed acute myeloid leukemia patients: A propensity score-matched analysis
    Wang, Rong
    Zhang, Yi
    Chang, Jie
    Wang, Huafeng
    Lou, Yinjun
    Yang, Min
    Xu, Gaixiang
    Tong, Hongyan
    Xie, Wanzhuo
    Zhou, De
    Wei, Juying
    Mai, Wenyuan
    Ye, Xiujin
    Meng, Haitao
    Jin, Jie
    Zhu, Hong-Hu
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (02)
  • [24] A comparative evaluation of gemtuzumab ozogamicin plus daunorubicin-cytarabine and other treatments for newly diagnosed acute myeloid leukemia
    Ashaye, Ajibade O.
    Khankhel, Zarmina
    Xu, Yingxin
    Fahrbach, Kyle
    Mokgokong, Ruth
    Orme, Michelle E.
    Lang, Kathryn
    Cappelleri, Joseph C.
    Mamolo, Carla
    FUTURE ONCOLOGY, 2019, 15 (06) : 663 - 681
  • [25] Tyrosine kinase inhibition in acute myeloid leukemia
    Altman, Jessica K.
    Szilard, Amy K.
    Platanias, Leonidas C.
    LEUKEMIA & LYMPHOMA, 2013, 54 (07) : 1351 - 1352
  • [26] CYTARABINE PLUS IDARUBICIN OR DAUNORUBICIN AS INDUCTION AND CONSOLIDATION THERAPY FOR PREVIOUSLY UNTREATED ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    WIERNIK, PH
    BANKS, PLC
    CASE, DC
    ARLIN, ZA
    PERIMAN, PO
    TODD, MB
    RITCH, PS
    ENCK, RE
    WEITBERG, AB
    BLOOD, 1992, 79 (02) : 313 - 319
  • [27] Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
    Lisa Kim
    Brian Fowler
    Courtney M. Campbell
    Jeremy Slivnick
    Haseeb Nawaz
    Yaquta Kaka
    Patrick Ruz
    Ajay Vallakati
    Ragavendra Baliga
    Sumithira Vasu
    Daniel Addison
    Cardio-Oncology, 7
  • [28] Acute cardiotoxicity after initiation of the novel tyrosine kinase inhibitor gilteritinib for acute myeloid leukemia
    Kim, Lisa
    Fowler, Brian
    Campbell, Courtney M.
    Slivnick, Jeremy
    Nawaz, Haseeb
    Kaka, Yaquta
    Ruz, Patrick
    Vallakati, Ajay
    Baliga, Ragavendra
    Vasu, Sumithira
    Addison, Daniel
    CARDIO-ONCOLOGY, 2021, 7 (01)
  • [29] Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
    Arwanih, Elly Y.
    Louisa, Melva
    Rinaldi, Ikhwan
    Wanandi, Septelia I.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (12)
  • [30] Outpatient Administration of Liposomal Daunorubicin and Cytarabine (Vyxeos) in Patients With Secondary Acute Myeloid Leukemia
    Kasner, Margaret T.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 604 - 606
12345